International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors

Neuro-Oncology

Volumn 13, Issue 6, 2011, Pages 649-659

  Lassman, Andrew B ^a   Iwamoto, Fabio M ^a,r   Cloughesy, Timothy F ^b   Aldape, Kenneth D ^c   Rivera, Andreana L ^c,s   Eichler, April F ^d   Louis, David N ^d   Paleologos, Nina A ^e   Fisher, Barbara J ^f   Ashby, Lynn S ^g   Gregory Cairncross, J ^h   Roldán, Gloria B ^h   Wen, Patrick Y ⁱ   Ligon, Keith L ⁱ   Schiff, David ^j   Ian Robins, H ^k   Rocque, Brandon G ^k   Chamberlain, Marc C ^l   Mason, Warren P ^m   Weaver, Susan A ⁿ   Green, Richard M ^o   Kamar, Francois G ^p,q   Abrey, Lauren E ^a   Deangelis, Lisa M ^a   Jhanwar, Suresh C ^a   Rosenblum, Marc K ^a   Panageas, Katherine S ^a   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^f LONDON REGIONAL CANCER PROGRAM   (Canada)

^g BARROW NEUROLOGICAL INSTITUTE   (United States)

^h UNIVERSITY OF CALGARY   (Canada)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^j UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^k UNIVERSITY OF WISCONSIN MADISON   (United States)

^l SEATTLE CANCER CARE ALLIANCE   (United States)

^m PRINCESS MARGARET HOSPITAL   (Canada)

ⁿ ALBANY MEDICAL CENTER   (United States)

^o KAISER PERMANENTE MEDICAL CENTER   (United States)

^p CLEMENCEAU MEDICAL CENTER   (Lebanon)

^q HOLY SPIRIT UNIVERSITY OF KASLIK USEK   (Lebanon)

^r NATIONAL CANCER INSTITUTE   (United States)

^s HOUSTON METHODIST HOSPITAL   (United States)

more..

Author keywords

1p19q; Oligo astrocytoma; Oligodendroglioma; PCV; Temozolomide

Indexed keywords

LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADULT; AGED; ANAPLASTIC CARCINOMA; ANAPLASTIC OLIGOASTROCYTOMA; ANAPLASTIC OLIGODENDROGLIOMA; ARTICLE; ASTROCYTOMA; BRAIN BIOPSY; BRAIN REGION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHROMOSOME 19Q; CHROMOSOME DELETION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; RETROSPECTIVE STUDY; TUMOR LOCALIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; COHORT STUDIES; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL AGENCIES; LOMUSTINE; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; PROCARBAZINE; RADIOTHERAPY; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 79959978296     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor040     Document Type: Article

References (30)

1. CBTRUS. Central Brain Tumor Registry of the United States 2008 statistical report: primary brain tumors in the Uninted States. 2008; http://www.cbtrus.org/. Accessed August 15, 2008.
2. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006;24:2707-2714. (Pubitemid 46630566)
3. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006;24:2715-2722. (Pubitemid 46630567)
4. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009;27:5874-5880.
5. Abrey LE, Louis DN, Paleologos N, et al. Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro-oncol. 2007;9:314-318. (Pubitemid 47169664)
6. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90:1473-1479. (Pubitemid 28482012)
7. DeAngelis LM. Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected]. J Clin Oncol. 2009;27:5861-5862.
8. Abrey LE, Childs BH, Paleologos N, et al. High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up. Neuro-oncol. 2006;8:183-188. (Pubitemid 46542663)
9. Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1994;12:2013-2021.
10. Levin VA, Edwards MS, Wright DC, et al. Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep. 1980;64:237-244.
11. Cairncross JG, Wang M, Chang S, et al. A randomized trial of chemotherapy plus radiotherapy (RT) versus RT alone for anaplastic oligodendroglioma (RTOG 9402): the perspective of longer follow-up [abstract]. Int J Radiat Oncol Biol Phys. 2008;72:S7-S8.
12. DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology. 1989;39:789-796. (Pubitemid 19150153)
13. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus wholebrain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10:1037-1044.
14. Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009;8:810-818.
15. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459-466.
16. Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978;49:333-343. (Pubitemid 9013313)
17. Weller M. Chemotherapy for low-grade gliomas: when? how? how long? Neuro Oncol. 2010;12:1013.
18. Vogelbaum MA, Berkey B, Peereboom D, et al. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro Oncol. 2009;11:167-175.
19. Burger PC. What is an oligodendroglioma? Brain Pathol. 2002;12:257-259. (Pubitemid 34259927)
20. Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol. 2010;28:4601-4608.
21. Morris PG, Lassman AB. Optimizing chemotherapy and radiotherapy for anaplastic glioma. Nat Rev Clin Oncol. 2010;7:428-430.
22. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
23. Macdonald DR, Cascino TL, Schold SC, Jr., Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280. (Pubitemid 20195640)
24. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963-1972.
25. Curran WJ, Jr., Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993;85:704-710. (Pubitemid 23133591)
26. Louis DN, Ohgaki H, Wiestler OD, Cavanee WK. WHO Classification of Tumours of the Central Nervous System. 4th ed. Lyon: International Agency for Research on Cancer; 2007.
27. van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res. 2010;16:1597-1604.
28. van den Bent MJ, Dubbink HJ, Sanson M, et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol. 2009;27:5881-5886.
29. Ney DE, Lassman AB. Molecular profiling of oligodendrogliomas: impact on prognosis, treatment, and future directions. Curr Oncol Rep. 2009;11:62-67.
30. Labussiere M, Idbaih A, Wang XW, et al. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology. 2010;74:1886-1890.